AmpliPhi Advances Phage In Clinic To Address Microbial Infections
Executive Summary
Emerging Company Profile: Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi has made progress in Phase I studies for its lead program. CEO Scott Salka explains to Mike Ward how he is looking to secure sufficient capital to support the Phase II development of AmpliPhi's lead program against chronic rhinosinusitis while advancing other product candidates.
You may also be interested in...
BioNotebook: Targacept, AcelRx/Grunenthal, Retrophin/Transcept, AmpliPhi
Targacept sinks on another failure; AcelRx signs EU Zalviso deal; Retrophin drops Transcept bid; and AmpliPhi nets $16.9m in stock sale.
AmpliPhi swallows SPS to expand bacteriophage breadth
Two companies specialising in bacteriophage technologies are to join forces as AmpliPhi, which has operations in the UK and US, prepares to acquire Sydney, Australia-based Special Phage Services (SPS). The all-share transaction will create "the world's leading anti-infective company focused on bacteriophage-based therapies", they claim.
AmpliPhi initially raises $2.7m private investment as part of planned $5m round
AmpliPhi Biosciences has closed an initial investment round, raising $2.7 million in equity investment and convertible loan notes to support the further progress of the company.